Professor Mark Wainwright has been involved in photosensitiser research and development since 1987, when he was a research fellow in drug discovery for the photodynamic therapy of cancer at the University of Leeds. For the past 25 years he has worked mainly in photodynamic infection control applications (photoantimicrobials), especially concerning conventional drug resistance. He joined Liverpool John Moores University (LJMU) in 2005 and with the University formed the spin-out drug-discovery company Pharmalucia in 2008. He has been Professor of Chemotherapy at LJMU since 2011. His book Photosensitisers in Biomedicine was published by Wiley in 2009.